(Q39610529)

13 September 2017

Retinoblastoma tumorigenesis: genetic and epigenetic changes walk hand in hand (English)

1 reference

13 September 2017

1 reference

1 reference

2

1 reference

13 September 2017

Petra Temming

1

1 reference

PubMed ID

22646767

13 September 2017

Dietmar R Lohmann

series ordinal

3

1 reference

PubMed ID

22646767

13 September 2017

language of work or name

English

0 references

publication date

1 May 2012

1 reference

13 September 2017

1 reference

13 September 2017

8

1 reference

13 September 2017

5

1 reference

13 September 2017

525-528

1 reference

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

13 September 2017

1 reference

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma.

21 January 2018

1 reference

Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.

21 January 2018

1 reference

Allelic loss in a minimal region on chromosome 16q24 is associated with vitreous seeding of retinoblastoma

21 January 2018

1 reference

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype

21 January 2018

1 reference

Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR.

21 January 2018

1 reference

Inactivation of the p53 pathway in retinoblastoma.

21 January 2018

1 reference

Cell-specific DNA methylation patterns of retina-specific genes

21 January 2018

1 reference

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

21 January 2018

1 reference

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

21 January 2018

1 reference

An epigenomic mechanism in retinoblastoma: the end of the story?

21 January 2018

1 reference

The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.12.41

1 reference

13 September 2017

1 reference

PubMed ID

22646767